Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions

Journal of Drugs in Dermatology

Volumn 13, Issue 3, 2014, Pages 252-256

  Menter, Alan ^a   Papp, Kim A ^b   Tan, Huaming ^c   Tyring, Steve ^d   Wolk, Robert ^c   Buonanno, Marjorie ^c  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b K Papp Clinical Research Inc   (Canada)

^c PFIZER INC   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOFACITINIB; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARM; ARTICLE; BODY REGIONS; BODY SURFACE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; HEAD; HUMAN; LEG; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NECK; PHASE 2 CLINICAL TRIAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT COURSE THERAPY; SKIN INDURATION; TARGET PLAQUE SEVERITY SCORE; TREATMENT DURATION; TREATMENT RESPONSE; TRUNK; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896372778     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg. 2010;29:3-9.
2. Chang BY, Zhao F, He X et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183:2183-2192.
3. Hsu S, Papp KA, Lebwohl MG et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95-102.
4. Papp K, Bissonnette R, Rosoph L et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1337-1342. (Pubitemid 351522314)
5. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol. 2005;152:597-615. (Pubitemid 40571289)
6. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther. 2003;25:2487-2505. (Pubitemid 37373927)
7. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448-459.
8. Papp K, Berth-Jones J, Kragballe K et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151-1160. (Pubitemid 47423401)
9. Crowley J. Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol. 2010;9:912-918.
10. Papp K, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668-677.
11. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157:238-244. (Pubitemid 8387357)
12. Wittkowski KM, Leonardi C, Gottlieb A et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6:e20279.
13. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60:1024-1031.